Video

Co-Clinical Trial Approach to Targeting the PI3K Pathway in Prostate Cancer

Name: Co-Clinical Trial Approach to Targeting the PI3K Pathway in Prostate Cancer
Uploaded: 2016-06-13T00:00:00+00:00
Description: Dr. Akash Patnaik, assistant professor of medicine, discusses the rationale for PI3k as a therapeutic target in prostate cancer and the mechanistic strategies to overcome de novo and acquired resistance to single agent PI3K inhibitors in co-clinical trials of prostate cancer. Dr. Patnaik also examines “co-clinical” PI3K inhibitor-based combination trials in PTEN-deficient prostate cancer.

Overview

Dr. Akash Patnaik, assistant professor of medicine, discusses the rationale for PI3k as a therapeutic target in prostate cancer and the mechanistic strategies to overcome de novo and acquired resistance to single agent PI3K inhibitors in co-clinical trials of prostate cancer. Dr. Patnaik also examines “co-clinical” PI3K inhibitor-based combination trials in PTEN-deficient prostate cancer.

Published

June 13, 2016

Created by

Related Presenters

Akash Patnaik, MD, PhD

Assistant Professor of Medicine

Akash Patnaik, MD, PhD, MMSc, is a medical oncologist specializing in the care of patients with genitourinary cancers, including prostate, bladder, kidney and testicular cancers. He also has a strong interest in the development of novel ...